Page last updated: 2024-11-08

desmethylselegiline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

desmethylselegiline: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID200718
CHEMBL ID1276
SCHEMBL ID4543249
MeSH IDM0068954
PubMed CID185859
CHEMBL ID145089
CHEBI ID79968
SCHEMBL ID2477570
MeSH IDM0068954

Synonyms (59)

Synonym
n-desmethyl-selegiline
desmethyldeprenyl
desmethylselegiline
demethyl-deprenyl-dmd
demethyldeprenyl-selegiline
benzeneethanamine, alpha-methyl-n-2-propynyl-
1-phenyl-2-(n-2-propynyl)aminopropane
alpha-methyl-n-2-propynylbenzeneethanamine
di-n-propargylamphetamine
CHEMBL1276
1-phenyl-n-prop-2-ynylpropan-2-amine
AKOS012315520
FT-0665706
18913-84-3
FT-0673065
nordeprenyl
SCHEMBL4543249
n-(1-methyl-2-phenylethyl)-2-propyn-1-amine #
J-012201
n-propargylamphetamine
DTXSID30891483
benzeneethanamine, |a-methyl-n-2-propyn-1-yl-
EN300-146886
(1-phenylpropan-2-yl)(prop-2-yn-1-yl)amine
benzeneethanamine, alpha-methyl-n-2-propyn-1-yl-
(-)-n-demethyl deprenyl
CS-0068673
n-desmethyl selegiline-d5/ desmethyl deprenyl-d5
HY-119532
norselegiline
56862-28-3
LOPAC0_000461
NCGC00162161-01
NCGC00162161-02
chebi:79968 ,
CHEMBL145089
rnordeprenyl
n-[(2r)-1-phenylpropan-2-yl]prop-2-yn-1-amine
(2r)-1-phenyl-n-prop-2-ynylpropan-2-amine
unii-5f44wr1i53
5f44wr1i53 ,
n-((2r)-1-phenylpropan-2-yl)prop-2-yn-1-amine
AKOS006240224
CCG-204553
l-nordeprenyl
l-desmethyldeprenyl
n-desmethylselegiline
(-)-desmethylselegiline
(-)-n-desmethylselegiline
UUFAJPMQSFXDFR-LLVKDONJSA-N
((r)-1-methyl-2-phenyl-ethyl)-prop-2-ynyl-amine
selegiline hydrochloride impurity d [ep impurity]
benzeneethanamine, .alpha.-methyl-n-2-propyn-1-yl-, (.alpha.r)-
SCHEMBL2477570
[(2r)-1-phenylpropan-2-yl](prop-2-yn-1-yl)amine
Q27149135
SDCCGSBI-0050446.P002
desmethyl selegiline
DTXSID001315731

Research Excerpts

Pharmacokinetics

Itraconazole had no significant effects on the pharmacokinetic variables. The AUC of desmethylselegiline was increased by about 10% (P < 0.1)

ExcerptReferenceRelevance
" This study aimed at examining whether the plasma pharmacokinetic parameters of cabergoline and selegiline are modified when given in combination."( Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline.
Bosc, M; Deffond, D; Dordain, G; Dostert, P; Fiorentini, F; La Croix, R; Persiani, S; Strolin Benedetti, M; Vernay, D, 1995
)
0.29
" As plasma levels of selegiline are very low and the elimination half-life is very short being about 9 minutes, therefore, a very sensitive and selective method for determining the 3 main metabolites desmethylselegiline (DMS), methamphetamine (MA) and amphetamine (A) was developed."( Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
Kikuta, C; Ludwig, G; Mascher, HJ; Millendorfer, A; Schiel, H, 1997
)
0.3
" As it became evident that the use of oral steroids had a drastic effect on selegiline concentrations, the pharmacokinetic analyses were performed separately for oral contraceptive users and those not receiving any concomitant medication."( Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.
Anttila, M; Helminen, A; Huupponen, R; Karnani, H; Laine, K, 1999
)
0.3
"The total AUC and Cmax of selegiline were 10-to 20-fold higher in those subjects taking oral steroids compared with subjects with no concomitant medication; this finding was consistent and statistically significant at all the four dose levels."( Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.
Anttila, M; Helminen, A; Huupponen, R; Karnani, H; Laine, K, 1999
)
0.3
" The pharmacokinetic profiles of selegiline and the metabolites were examined from serum samples for 24 hours (i."( Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
Anttila, M; Heinonen, E; Huupponen, R; Laine, K; Mäki-Ikola, O,
)
0.13
"Unlike oral contraceptives, HRT is not likely to have clinically significant pharmacokinetic interaction with selegiline."( Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
Anttila, M; Laine, K; Nyman, L; Palovaara, S, 2002
)
0.31
" The main pharmacokinetic parameters (C(max), t(max), t1/2beta, AUC(0-6), AUC(0-infinity)) have been calculated."( Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.
Lengyel, J; Magyar, K; Szatmáry, I; Szebeni, G, 2007
)
0.34
" Oral fluid (OF) has been successfully used as an alternative matrix for blood testing in several pharmacokinetic studies."( Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline.
Chen, L; Duan, G; Shen, B; Shi, Y; Wang, S; Xiang, P; Yan, H; Yu, Y, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" An open, randomized, 2-way cross-over study was performed in 24 healthy male volunteers to determine bioavailability and pharmacokinetic parameters of 2 oral selegiline preparations after single dose administration."( Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl).
Ludwig, G; Michaelis, K; Pabst, G; Reh, C; Waitzinger, J, 1996
)
0.29
"An open-label, four-way crossover, single dose pharmacokinetic study comparing the bioavailability of 10 mg selegiline hydrochloride administered to healthy young males as a solution by the oral route (in the stomach) and by a nasoenteric tube to the following three sites: duodenum, jejunum and terminal ileum was conducted."( Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett, JS; De Witt, KE; Ireland, J; Morales, RJ; Rajewski, G; Rohatagi, S; Szego, P, 1996
)
0.29
"A bioavailability study of 2 different selegiline preparations were conducted in 20 healthy volunteers to test the bioequivalence."( Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
Kikuta, C; Ludwig, G; Mascher, HJ; Millendorfer, A; Schiel, H, 1997
)
0.3
" The area under the concentration-time curve from time 0 to 24 hours (AUC0-24) of desmethylselegiline was 33 times higher than that of selegiline, suggesting a better bioavailability of desmethylselegiline."( Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
Anttila, MI; Heinonen, EH; Karnani, HL; Lammintausta, RA; Nyman, LM; Pyykkö, KA; Vuorinen, JA, 1997
)
0.3
"Concomitant use of oral contraceptives caused a drastic (20-fold) increase in the oral bioavailability of selegiline."( Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.
Anttila, M; Helminen, A; Huupponen, R; Karnani, H; Laine, K, 1999
)
0.3
" (-)-Deprenyl is well absorbed after oral and parental treatment."( Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.
Lengyel, J; Magyar, K; Szatmáry, I; Szebeni, G, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" While both AMP and MET exposure was equivalent at all dosing sites, DMS exposure was less (approximately 18%) at the terminal ileum."( Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett, JS; De Witt, KE; Ireland, J; Morales, RJ; Rajewski, G; Rohatagi, S; Szego, P, 1996
)
0.29
" AMP and MET metabolites were insensitive to dosing site consistent with their hepatic formation."( Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett, JS; De Witt, KE; Ireland, J; Morales, RJ; Rajewski, G; Rohatagi, S; Szego, P, 1996
)
0.29
" The sole recommended dosing regimen is 5 mg given in the morning and at noon with breakfast and lunch."( Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
Barrett, JS; DeWitt, KE; Lessard, D; Morales, RJ; Rohatagi, S, 1997
)
0.3
" The present results suggest that concomitant use of selegiline with exogenous female sex steroids should be avoided or the dosage of selegiline should be reduced in order to minimize the risks of selegiline related adverse drug reactions."( Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.
Anttila, M; Helminen, A; Huupponen, R; Karnani, H; Laine, K, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amphetaminesAmines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency37.68580.035520.977089.1251AID504332
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency8.49210.134610.395030.1313AID1347049
chromobox protein homolog 1Homo sapiens (human)Potency0.89130.006026.168889.1251AID488953
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)Activity0.00130.00080.00120.0014AID125378
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)Activity0.00120.00080.00110.0014AID125378; AID125701
Amine oxidase [flavin-containing] AMus musculus (house mouse)Activity0.00120.00060.00110.0014AID125378; AID125701
Amine oxidase [flavin-containing] BMus musculus (house mouse)Activity0.00110.00050.00100.0014AID125378; AID126675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID229512Ratio of IC50 value against MAO-A to that of MAO-B.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
AID126837In vitro inhibitory concentration against Monoamine oxidase B of rat brain homogenates; value ranges from 0.27-0.362002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
AID125864In vitro inhibitory concentration against Monoamine oxidase A of rat brain homogenates; value ranges from 100-3402002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID125701The ability of the compound(25 umol/kg/day) to inactivate monoamine oxidase A(MAO-A) was tested on brain mitochondrial membranes of mice, for 3 day.1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl-1,2,3,6-tetrahydropyrid-4-yl carbamate derivatives: potential prodrugs of (R)- and (S)-nordeprenyl.
AID126675The ability of the compound(25 umol/kg/day) to inactivate monoamine oxidase B (MAO-B) was tested on brain mitochondrial membranes of mice, for 3 day.1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl-1,2,3,6-tetrahydropyrid-4-yl carbamate derivatives: potential prodrugs of (R)- and (S)-nordeprenyl.
AID230685Ratio of activities of MAO-B / MAO-A1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl-1,2,3,6-tetrahydropyrid-4-yl carbamate derivatives: potential prodrugs of (R)- and (S)-nordeprenyl.
AID235091Residual activity was obtained.1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl-1,2,3,6-tetrahydropyrid-4-yl carbamate derivatives: potential prodrugs of (R)- and (S)-nordeprenyl.
AID125378The ability of the compound(25 umol/kg/day) to inactivate monoamine oxidase (MAO) was tested on brain mitochondrial membranes of mice, for 3 days.1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl-1,2,3,6-tetrahydropyrid-4-yl carbamate derivatives: potential prodrugs of (R)- and (S)-nordeprenyl.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's18 (33.96)18.2507
2000's23 (43.40)29.6817
2010's7 (13.21)24.3611
2020's5 (9.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.19 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (28.57%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (2.38%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other29 (69.05%)84.16%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]